View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Editas Medicine Announces First Quarter 2024 Results Conference Call a...

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that it will host a conference call and webcast on Wednesday, May 8, 2024, at 8:00 a.m. ET to discuss results for the first quarter 2024 and to provide a corporate update. To access the conference call: U.S. callers should dial and international callers should dial approximately five minutes before the call begins.Participants should ask to be c...

 PRESS RELEASE

Dentsply Sirona Reports First Quarter 2024 Results

Dentsply Sirona Reports First Quarter 2024 Results Net sales of $953 million decreased (2.6%), organic sales decreased (1.9%)GAAP gross margin of 53.1%, GAAP net income of $18 million or $0.09 per shareAdjusted EBITDA margin of 16.8%, adjusted EPS of $0.42Maintaining FY24 outlook for organic sales and adjusted EPS, trending towards the low-end of both ranges; reported sales adjusted for additional foreign currency impactCompany expects to repurchase up to $150 million of its common stock in Q2 2024 CHARLOTTE, N.C, May 02, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” o...

 PRESS RELEASE

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Coll...

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimm...

 PRESS RELEASE

Flexsteel Industries, Inc. Reports Strong Fiscal Third Quarter 2024 Re...

DUBUQUE, Iowa--(BUSINESS WIRE)-- Flexsteel Industries, Inc. (NASDAQ: FLXS) (“Flexsteel” or the “Company”), one of the largest manufacturers, importers, and marketers of residential furniture products in the United States, today reported third quarter fiscal 2024 results. Key Results for the Third Quarter Ended March 31, 2024 Strong sales growth of 8.2%. Net sales for the quarter of $107.2 million compared to $99.1 million in the prior year quarter. Robust sales orders of $111.5 million representing growth of $12.2M, or 12.3%, compared to the prior year quarter. Significant gross mar...

 PRESS RELEASE

Flexsteel to Appoint Derek P. Schmidt as President and CEO

DUBUQUE, Iowa--(BUSINESS WIRE)-- Flexsteel Industries, Inc. (NASDAQ:FLXS), announces the appointment of Derek P. Schmidt to the position of President and Chief Executive Officer effective July 1, 2024. Mr. Schmidt will succeed Jerald K. Dittmer who has announced his resignation from the position of Chief Executive Officer effective June 30, 2024, and retirement from Flexsteel on December 31, 2024. Derek P. Schmidt joined Flexsteel as Chief Financial Officer & Chief Operating Officer in April 2020 and was subsequently appointed Secretary and Treasurer in May 2020. In June 2022, his role as Ch...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Antoine Legault ... (+2)
  • Antoine Legault
  • Gerald Pascarelli
 PRESS RELEASE

Teledyne e2v and Airy3D collaboration delivers more affordable 3D visi...

Teledyne e2v and Airy3D collaboration delivers more affordable 3D vision solutions GRENOBLE, France, April 23, 2024 (GLOBE NEWSWIRE) -- Teledyne e2v, a Teledyne Technologies [NYSE: TDY] company and global innovator of imaging solutions, is pleased to announce a new technology and design collaboration with (Montreal, Canada), a leading 3D vision solution provider. The first result of this partnership is the co-engineering of the recently announced ™, a low-cost, low power, passive, 2 megapixel global shutter sensor which produces 2D images and 3D depth maps. Arnaud Foucher, Business Team...

 PRESS RELEASE

Editas Medicine to Present Pre-clinical Data Demonstrating Progression...

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to ...

Antoine Legault ... (+2)
  • Antoine Legault
  • Gerald Pascarelli
 PRESS RELEASE

Flexsteel Industries, Inc. to Announce Third Quarter 2024 Results on A...

DUBUQUE, Iowa--(BUSINESS WIRE)-- Flexsteel Industries, Inc. (NASDAQ:FLXS) (“Flexsteel” or the “Company”), one of the largest manufacturers, importers, and marketers of residential furniture products in the United States, announced today that it will issue its third quarter 2024 financial results after market close on Monday, April 29, 2024. A conference call and audio webcast with analysts and investors will be held on Tuesday, April 30, 2024, at 8:00 a.m. Central Time to discuss the results and answer questions. Live conference call: 833-816-1123 (domestic) or 412-317-0710 (international...

 PRESS RELEASE

Teledyne FLIR Defense Awarded $249 Million IDIQ Contract for U.S. Mari...

BOSTON--(BUSINESS WIRE)-- Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract worth up to $249 million by the U.S. Marine Corps Systems Command for its Organic Precision Fires-Light (OPF-L) program. The initial delivery order is valued at $12 million. This press release features multimedia. View the full release here: Teledyne FLIR Defense has been awarded a contract worth up to $249 million by the United States Marine Corps for its Organic Precision Fires-Light (OPF-L) prog...

 PRESS RELEASE

Dentsply Sirona to Host First Quarter Conference Call on May 2nd

Dentsply Sirona to Host First Quarter Conference Call on May 2nd CHARLOTTE, N.C., April 09, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 2, 2024, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company’s website at Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company’s we...

Teledyne Technologies Incorporated: Update to credit analysis followin...

Our credit view of this issuer reflects its expectations of steady operating performance, against its aggressive acquisition strategy.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch